Documentary and Research Spotlight Workplace Neglect of Endometriosis

Key facts

The release of a new documentary film focusing on the personal and professional toll of endometriosis has galvanized renewed scrutiny over how corporate America and global employers handle chronic gynaecological health. As reported by Fortune, the film presents detailed accounts of individuals attempting to navigate demanding careers while suffering from an often debilitating condition that medicine has struggled to diagnose and treat efficiently.

Endometriosis occurs when tissue similar to the lining of the uterus grows outside the organ, establishing lesions, cysts, and scar tissue on the ovaries, fallopian tubes, outer uterine wall, bowel, and pelvic lining. During menstrual cycles, this tissue responds to hormonal signals by swelling and bleeding internally. Unlike normal uterine tissue, which sheds through menstruation, this blood has no exit route, triggering severe chronic inflammation, nerve irritation, internal adhesions, and intense pain flares.

The documentary and accompanying research highlighted by Fortune detail how these physical realities collide directly with standard workplace expectations. Patients frequently endure extreme abdominal pain, lower back discomfort, nausea, fatigue, and gastrointestinal distress during symptom spikes. Because these symptoms can occur unpredictably or cycle around menstruation, affected workers face recurring periods where maintaining standard office attendance or sustained physical activity becomes impossible.

The research examined in the reporting reveals that many employees choose to conceal their diagnosis from managers and colleagues due to social stigma, fear of professional retaliation, or concerns about being perceived as uncommitted. When forced to miss work, employees often exhaust personal vacation days or take unpaid leave rather than disclosing pelvic health issues. The findings also document widespread presenteeism—the phenomenon of working while physically compromised—which lowers daily output while aggravating the underlying health condition.

Why it matters

The systemic failure of employers to address endometriosis carries significant economic, social, and structural consequences. At an enterprise level, unaddressed chronic illness drains organizational productivity. When employees feel compelled to work through severe pain flares without flexibility or remote options, their cognitive capacity and work speed decline, leading to burnout and elevated turnover rates. The annual financial burden of lost productivity attributed to endometriosis runs into the tens of billions of dollars globally, surpassing the healthcare expenditures associated with many other chronic conditions.

From an equity perspective, endometriosis predominantly impacts individuals during their peak productive and career-building years, typically between ages 15 and 49. Because the disease frequently disrupts education, early career momentum, and performance evaluations during critical promotional windows, it serves as a silent driver of the gender pay gap. Women managing chronic pelvic pain are disproportionately forced to accept lower-paying part-time work, pause their professional advancement, or leave the workforce entirely to manage their health.

Furthermore, existing employment protection frameworks are ill-suited for fluctuating chronic illnesses. Short-term disability programs and standard sick leave policies in most jurisdictions are designed around continuous, linear recoveries, such as post-surgical healing or acute infections. Endometriosis, by contrast, operates in episodic cycles. Without tailored accommodations—such as flexible scheduling, task adjustments, and non-punitive leave accounting—corporate wellness initiatives remain fundamentally incomplete, leaving vulnerable employees unprotected under standard benefit structures.

Endometriosis was first pathologically identified in the late 19th century, yet it remains one of the most historically underfunded and misunderstood areas of modern medicine. For decades, medical textbooks and healthcare providers categorized severe pelvic pain as a normal component of menstruation or dismissed it as a psychosomatic complaint. This pervasive clinical bias contributed to a phenomenon known as the gender pain gap, in which symptoms reported by female patients are systematically minimized or diagnosed later than equivalent complaints in male counterparts.

The path to a definitive diagnosis has historically required laparoscopic surgery, an invasive procedure in which a surgeon inserts a camera through abdominal incisions to visually inspect and biopsy tissue lesions. While specialized high-resolution magnetic resonance imaging (MRI) and advanced transvaginal ultrasound protocols have improved non-invasive detection in recent years, surgical confirmation remains the clinical gold standard. Consequently, patients routinely consult multiple physicians over a period of seven to ten years before receiving an accurate diagnosis.

On the regulatory front, legislative recognition of gynaecological health in the workplace has evolved unevenly across the globe. In February 2023, Spain made international headlines by passing a comprehensive reproductive health law that included state-funded paid medical leave for workers suffering from incapacitating menstrual pain, requiring a doctor's confirmation. A small number of Asian nations, including Japan, South Korea, and Indonesia, have maintained statutory menstrual leave provisions on their books for decades, though cultural stigmas often suppress utilization.

In contrast, in the United States and the United Kingdom, employees seeking protection must rely on broader disability legislation, such as the Americans with Disabilities Act (ADA) or the Equality Act 2010. These frameworks require employees to prove that their condition substantially limits major life activities over a sustained period. Because endometriosis symptoms fluctuate in intensity, workers often face onerous legal and administrative hurdles when requesting reasonable accommodations from human resource departments.

Reaction

The reporting on the new documentary has drawn strong commentary from patient advocates, healthcare specialists, and labor advisors, who argue that corporate policies must evolve beyond superficial wellness programs. Advocacy organizations, including the Endometriosis Foundation of America and Endometriosis UK, have long campaigned for workplace education campaigns that demystify pelvic health and train line managers to handle disclosure requests with confidentiality and empathy.

Human resource professionals and workplace equity consultants have noted that while the widespread adoption of remote and hybrid work models following the 2020 COVID-19 pandemic provided informal relief for some sufferers, informal flexibility is insufficient. Without explicit, written policy protections, workers remain subject to the individual biases of line managers. Advocates emphasize that clear administrative frameworks are essential to ensure that accommodations are granted consistently and without penalty to career progression.

While major corporate industry groups have not issued formal collective statements regarding the film's release, benefit managers across large enterprises are facing growing pressure from employee resource groups to re-examine chronic condition management, fertility benefits, and specialized health leaves.

What we don't know yet

Despite growing clinical interest and public advocacy, substantial gaps remain in both medical understanding and corporate policy data regarding endometriosis. Scientists have yet to identify the exact etiology of the disease. While retrograde menstruation—a process where menstrual blood flows backward through the fallopian tubes into the pelvic cavity—remains a leading theory, it fails to explain why tissue lesions develop in non-reproductive organs or in rare cases among individuals without a uterus. Alternative theories involving cellular metaplasia, genetic predisposition, and immune system dysfunction remain under active investigation.

Additionally, long-term data on the effectiveness of non-hormonal therapeutic interventions in clinical trials is still pending. Current medical management relies heavily on hormonal suppression or repeated surgical excisions, both of which carry significant side effects and high recurrence rates.

It also remains unclear how broadly private enterprise will adopt formal endometriosis or reproductive health leave policies in the absence of statutory mandates. Researchers have limited empirical data tracking whether corporate adoption of flexible leave leads to measurable gains in employee retention and health outcomes over multi-year periods.

What to watch

In the coming months, public reaction to the documentary will serve as a bellwether for legislative and corporate policy shifts. Key indicators to monitor include:

This report is based on original reporting published by Fortune on September 21, 2026.